All logins are passed through a 256 bit (AES-256) SSL certificate. Even if you don't see the https:// link, please rest assured that it is being used. If you prefer, you can login via a page where the certificate is "visible":
Community Menu
PDFProject 4 - Modulation of the Renal Fibrogenic Response by Cathepsins
This page document is being viewed within the PCEN Projects collection.
Last modified on January 23, 2012 at 1:27 PM by Dominique Brand
Summary description:
Summary description:
Project Director: Allison Eddy, M.D.
Consultant: Scott Turner, Ph.D.
CKD is a major risk factor for cardiovascular disease (5x increased risk). An estimated 28 million adult Americans have CKD; a subset (currently > 500,000) will survive long enough to need dialysis or a kidney transplant. At this time, no therapy is known to have a clinically significant impact on CKD progression rates. The goal of the proposed research is to develop a scientific foundation and rationale for new CKD therapies.
